Moonlight Therapeutics, Inc.
Marietta, GA
- UEI
- S6TTK8Y6R5A1
- CAGE
- 827T9
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2785 Stone Hall Dr, Marietta, GA 30062, USA
- Website
- moonlighttx.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| General Nutraceutical Technology, LLC | Briarcliff Manor, NY | 541713 Research and Development in Nanotechnology |
| Allergychoices LLC | Onalaska, WI | 325412 Pharmaceutical Preparation Manufacturing |
| Alerje, Inc. | Kalamazoo, MI | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Guy's And ST Thomas' NHS Foundation Trust | England | — |
About the company
Moonlight Therapeutics, Inc. is a minority-owned, for-profit corporate entity based in Marietta, Georgia, that specializes in developing innovative medical technologies focused on allergen immunotherapy. The company is registered in SAM.gov and has a primary focus on developing microneedle-based treatments for food allergies, with a particular emphasis on peanut allergy treatment. Their core technology involves a targeted approach to administering allergens into the top skin layers to desensitize allergic patients using microneedle technology, which allows for precise and minimally invasive delivery of allergens near immune cells.
The company has been awarded multiple federal grants from key agencies like the National Institute of Allergy and Infectious Diseases and the Department of the Army Medical Command to advance its research and development efforts. Their primary project, called TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin), aims to develop a novel treatment for peanut allergies that could potentially reduce the risk of anaphylactic reactions. The grants, totaling approximately $3.3 million, support various stages of research including pre-clinical development, manufacturing scale-up of microneedle technology, and clinical trials to evaluate the safety and tolerability of their innovative treatment approach. The grants specifically focus on developing a microneedle stamp for peanut allergen immunotherapy, with potential future applications for treating multiple food allergies simultaneously, addressing a significant unmet medical need affecting millions of people in the United States and Europe.
Quick answers
Is Moonlight Therapeutics, Inc. registered in SAM.gov?
Yes. Moonlight Therapeutics, Inc.'s SAM.gov registration is active through September 17, 2027.
What is Moonlight Therapeutics, Inc.'s most recent federal award?
Moonlight Therapeutics, Inc.'s most recent federal grant award is Development of a peanut allergy treatment for adults using microneedles (HT94252510548), from Defense Health Agency, on July 1, 2025.
On GovTribe
See Moonlight Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors